News: Overview

With ambitious goals and compelling technology, Graphite Bio is frequently in the news. Keep up on the latest press releases and select stories below.

Press Release | February 24, 2021

Graphite Bio Expands Leadership Team with Appointment of Jerry Cacia as Chief Technical Officer

Press Release | January 13, 2021

Jasper Therapeutics and Graphite Bio Announce Collaboration to Evaluate JSP191 as Conditioning Regimen for Novel Gene Replacement Therapy in Patients with XSCID

Corporate Presentation | January 12, 2021

Graphite Bio Presentation at 39th Annual J.P. Morgan Healthcare Conference

Download the Corporate Presentation Deck (PDF)

Press Release | January 8, 2021

Graphite Bio to Present at the 39th Annual J.P. Morgan Healthcare Conference

Press Release | December 21, 2020

Graphite Bio Appoints Pharmaceutical Industry Veterans to Board of Directors

Press Release | December 14, 2020

Graphite Bio Receives IND Clearance to Initiate Clinical Trial for Next-Generation Gene Editing Therapy GPH101 in Sickle Cell Disease

Press Release | November 9, 2020

Graphite Bio Expands Leadership Team with Accomplished Pharmaceutical Executives to Advance Programs to the Clinic and to Achieve Continued Business Growth

News Article | September 16, 2020

Endpoints: Versant Teams Up with Stanford Gene Editing Experts on a $45M Next-Gen Play — Marrying CRISPR and AAV to Fix Sickle Cell 

News Article | September 16, 2020

FierceBiotech: Graphite Bio debuts with $45M to cure sickle cell disease using gene edits  

Press Release | September 16, 2020

Graphite Bio Launches with $45 Million Series A Financing